Enzyvant Sciences Ltd.
24 articles with Enzyvant Sciences Ltd.
The incidence of congenital athymia is about 17 to 24 lives births each year in the U.S. The therapy is a one-time regenerative tissue-based therapy.
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Enzyvant announced the U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for immune reconstitution in pediatric patients with congenital athymia.
Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.
ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
Enzyvant announced the resubmission of the Biologics Licensing Application to the U.S. Food and Drug Administration for RVT-802, cultured human thymus tissue.
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
Former COO of Compass and Horizon Discovery joins Enzyvant as company nears first potential drug approval
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform designed to treat profound immunodeficiencies
Enzyvant's Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting
Enzyvant announced that its investigational regenerative treatment in late-stage development for congenital athymia will be featured during a platform presentation, at a symposium, and in a poster session at the Clinical Immunology Society 2019 annual meeting in Atlanta, GA, April 4-7.
Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare diseases, today announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Fast Track designations for RVT-801, an investigational enzyme replacement therapy.
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
Enzyvant, a biopharmaceutical company focused on developing transformative therapies for patients with rare diseases, announced the appointment of Rachelle Jacques as Chief Executive Officer.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
Enzyvant is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases.
Enzyvant announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company.
Enzyvant Sciences, one of Vivek Ramaswamy’s numerous ‘Vant’ companies, filed a rolling submission of a Biologics License Application (BLA) for RVT-802 with the U.S. Food and Drug Administration for the treatment of DiGeorge Anomaly (cDGA), an immunodeficiency disease that impacts infants.
Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly
Rolling BLA submission has been agreed to by FDA and is intended to expedite the Agency's review process
Enzyvant Announces Collaboration with Visikol to Develop Innovative Digital Pathology Assay to Support RVT-802 Development
Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.
Enzyvant Expands Executive Leadership Team with Appointments of Alan Kimura as Chief Medical Officer and Tamara Joseph as General Counsel
Enzyvant nannounced the appointments of Alan Kimura, MD, PhD as Chief Medical Officer and Tamara Joseph, JD, LLM as General Counsel.
Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to...